Some studies have suggested that immunosuppression with the mammalian targets of rapamycin (mTOR) inhibitor, such as everolimus or sirolimus, may reduce the risk of HCC recurrence after LT [46]. This evidence concerns the gene MTOR and hepatocellular carcinoma.